<DOC>
	<DOCNO>NCT01053104</DOCNO>
	<brief_summary>To develop system manage side effect adjust chemotherapy dose patient receive personal maximum tolerate dose .</brief_summary>
	<brief_title>Dose Adaptation Capecitabine Using Mobile Phone Toxicity Monitoring</brief_title>
	<detailed_description>Patients metastatic colorectal breast cancer recruit . - Metastatic Colorectal Cancer : capecitabine alone capecitabine + oxaliplatin 8 3-week cycle - Metastatic Breast Cancer : capecitabine alone capecitabine + docetaxel 8 3-week cycle . All patient give mobile phone onto enter side-effects experience prior take capecitabine morning evening . Any grade 3 4 symptom trigger alert pager hold ward-staff immediate attention . Thus , patient ' severe side-effects monitor real time trial allow real-time dose reduction cycle dose-increases clinic . Patient experience trial also evaluate participation trial . Patients already receive drug prior study administer patient part study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Metastatic colorectal breast cancer patient commence treatment one four specify regimen For metastatic colorectal cancer : capecitabine 2000mg/m2 114 , q 3 weekly oxaliplatin 130mg/m2 d1 q 3 weekly ( CAPOX ) capecitabine 2500mg/m2 114 , q 3 weekly For metastatic breast cancer : capecitabine 2000mg/m2d 114 , q 3 weekly capecitabine 2000mg/m2 114 , q 3 weekly docetaxel 75mg/m2 d1 q 3 weekly Age &gt; 18 year Fit start full ( 100 % ) start dose drug Able willing use mobile phone Reasonable renal , liver bone marrow function Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L Total bilirubin &lt; 1.5 ULN ALT , AST &lt; 2.5 x ULN Alkaline phosphatase &lt; 2.5 x ULN No obvious contra indication capecitabine oxaliplatin docetaxel Patients must also able read , write understand English . Patients live area Vodafone Orange mobile phone network Patients participate cancer treatment trial Moderate severe renal impairment [ creatinine clearance &lt; 30ml/min ( calculate accord CockroftGault formula ) ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Mobile phone</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Metastatic</keyword>
</DOC>